BWXT Names Vittorio Puppo President of Medical Business
BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical , effective August 12, 2024. Puppo brings over 30 years of experience in imaging, nuclear medicine, radiation therapy, and biotech. He previously served as COO of Radiopharm Theranostics and held various positions at Bracco, including chief marketing and strategy officer.
Puppo succeeds Jonathan Cirtain, who will transition back to his role as BWXT's chief development officer. BWXT Medical manufactures custom radiopharmaceuticals, radiotherapies, and medical isotopes in Ottawa and at TRIUMF's commercial cyclotron facility. The company aims to deliver high-quality nuclear medical products and solutions to improve patient outcomes worldwide.
BWX Technologies, Inc. (NYSE: BWXT) ha nominato Vittorio Puppo presidente di BWXT Medical, con effetto dal 12 agosto 2024. Puppo porta con sé oltre 30 anni di esperienza in imaging, medicina nucleare, radioterapia e biotecnologie. In precedenza, ha ricoperto il ruolo di COO in Radiopharm Theranostics e ha avuto diverse posizioni in Bracco, inclusi quelli di chief marketing e strategy officer.
Puppo succede a Jonathan Cirtain, che tornerà al suo incarico come chief development officer di BWXT. BWXT Medical produce radiofarmaci personalizzati, radioterapie e isotopi medici a Ottawa e presso la struttura cyclotron commerciale di TRIUMF. L'azienda mira a fornire prodotti e soluzioni nucleari mediche di alta qualità per migliorare gli esiti dei pazienti in tutto il mondo.
BWX Technologies, Inc. (NYSE: BWXT) ha nombrado a Vittorio Puppo como presidente de BWXT Medical, con efecto a partir del 12 de agosto de 2024. Puppo aporta más de 30 años de experiencia en imágenes, medicina nuclear, terapia de radiación y biotecnología. Anteriormente, se desempeñó como COO de Radiopharm Theranostics y ocupó varios puestos en Bracco, incluyendo el de director de marketing y estrategia.
Puppo sucede a Jonathan Cirtain, quien regresará a su papel como director de desarrollo de BWXT. BWXT Medical fabrica radiofármacos personalizados, radioterapias e isótopos médicos en Ottawa y en la instalación de ciclotrón comercial de TRIUMF. La empresa tiene como objetivo ofrecer productos y soluciones nucleares médicos de alta calidad para mejorar los resultados de los pacientes en todo el mundo.
BWX Technologies, Inc. (NYSE: BWXT)는 Vittorio Puppo를 BWXT Medical의 사장으로 임명하였으며, 이는 2024년 8월 12일부터 효력이 발생합니다. Puppo는 영상 촬영, 방사선 의학, 방사선 치료 및 생명공학 분야에서 30년 이상의 경험을 가지고 있습니다. 그는 이전에 Radiopharm Theranostics의 COO로 근무했으며, Bracco에서 마케팅 및 전략 책임자로서 여러 직책을 역임했습니다.
Puppo는 Jonathan Cirtain의 후임이며, Cirtain은 BWXT의 최고 개발 책임자로 복귀할 예정입니다. BWXT Medical은 오타와와 TRIUMF의 상업용 사이클로트론 시설에서 맞춤형 방사성 의약품, 방사선 치료 및 의학적 동위원소를 제조합니다. 이 회사는 전 세계 환자의 결과를 개선하기 위해 고품질의 핵 의학 제품과 솔루션을 제공하는 것을 목표로 하고 있습니다.
BWX Technologies, Inc. (NYSE: BWXT) a nommé Vittorio Puppo président de BWXT Medical, à compter du 12 août 2024. Puppo possède plus de 30 ans d'expérience dans le domaine de l'imagerie, de la médecine nucléaire, de la radiothérapie et de la biotechnologie. Auparavant, il a été COO de Radiopharm Theranostics et a occupé plusieurs postes chez Bracco, notamment celui de directeur marketing et stratégie.
Puppo succède à Jonathan Cirtain, qui retournera à son rôle de directeur du développement chez BWXT. BWXT Medical fabrique des radio-pharmaceutiques sur mesure, des radiothérapies et des isotopes médicaux à Ottawa et dans l'installation commerciale de cyclotron de TRIUMF. L'entreprise vise à fournir des produits et solutions de médecine nucléaire de haute qualité pour améliorer les résultats des patients dans le monde entier.
BWX Technologies, Inc. (NYSE: BWXT) hat Vittorio Puppo zum Präsidenten von BWXT Medical ernannt, ab dem 12. August 2024. Puppo bringt über 30 Jahre Erfahrung in den Bereichen Bildgebung, nuklearmedizinische Therapie, Strahlentherapie und Biotechnologie mit. Zuvor war er COO von Radiopharm Theranostics und hatte verschiedene Positionen bei Bracco inne, darunter Chief Marketing und Strategy Officer.
Puppo folgt auf Jonathan Cirtain, der in seine Rolle als Chief Development Officer von BWXT zurückkehren wird. BWXT Medical produziert maßgeschneiderte Radiopharmazeutika, Strahlentherapien und medizinische Isotope in Ottawa und in der kommerziellen Zyklotronanlage von TRIUMF. Das Unternehmen verfolgt das Ziel, hochwertige nuklearmedizinische Produkte und Lösungen anzubieten, um die Ergebnisse für Patienten weltweit zu verbessern.
- Appointment of experienced industry veteran Vittorio Puppo as president of BWXT Medical
- Puppo brings over 30 years of experience in imaging, nuclear medicine, radiation therapy, and biotech
- BWXT Medical's focus on delivering high-quality nuclear medical products and solutions
- None.
Puppo brings a wealth of experience to BWXT Medical, with over 30 years of experience in the areas of imaging, nuclear medicine, radiation therapy and biotech, in both
“Vittorio’s extensive experience, strategic insight and commitment to the medical manufacturing industry make him an ideal fit to lead our medical business into its next phase of growth and innovation,” said John MacQuarrie, president of BWXT commercial operations. “We’re confident that, under his leadership, BWXT Medical will continue to thrive and deliver increasing value to our customers and collaborators.”
“I am honored to join BWXT Medical and lead such a talented team dedicated to making a positive impact in the healthcare industry,” said Puppo. “I look forward to building on the company’s strong foundation and driving forward its vision of innovation, quality and customer-centricity. Together, we will continue to develop cutting-edge medical solutions that address the evolving needs of our customers, healthcare providers and their patients.”
Puppo holds a degree in finance and economics and a Master of Business Administration from the SDA Bocconi School of Management in
Puppo succeeds Jonathan Cirtain, whose expertise and dedication have been instrumental to BWXT Medical’s progress to-date. Cirtain will transition back full-time into his role as BWXT’s chief development officer, continuing to support BWXT Medical, along with the company’s broader innovation goals.
About BWXT Medical Ltd.
BWXT Medical Ltd. manufactures custom radiopharmaceuticals, radiotherapies and medical isotopes in an 80,000-square-foot cGMP manufacturing facility in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806549933/en/
Media Contact
Monifa Miller
Senior Director, Corporate Affairs
Commercial Operations
519.242.8071 mamiller@bwxt.com
Investor Contact
Chase Jacobson
Vice President, Investor Relations
980.365.4300 investors@bwxt.com
Source: BWX Technologies, Inc.
FAQ
When will Vittorio Puppo start as president of BWXT Medical ?
What is Vittorio Puppo's background before joining BWXT Medical?
What does BWXT Medical manufacture?
Who did Vittorio Puppo replace as president of BWXT Medical?
